APA (7th ed.) Citation

LR, G., Y, T., MS, W., WL, X., SR, Q., YW, S., . . . NN, L. (2023). Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac. Frontiers in oncology, 13, 1039901. https://doi.org/10.3389/fonc.2023.1039901

Chicago Style (17th ed.) Citation

LR, Gao, et al. "Assessment of Delivered Dose in Prostate Cancer Patients Treated with Ultra-hypofractionated Radiotherapy on 1.5-Tesla MR-Linac." Frontiers in Oncology 13 (2023): 1039901. https://doi.org/10.3389/fonc.2023.1039901.

MLA (9th ed.) Citation

LR, Gao, et al. "Assessment of Delivered Dose in Prostate Cancer Patients Treated with Ultra-hypofractionated Radiotherapy on 1.5-Tesla MR-Linac." Frontiers in Oncology, vol. 13, 2023, p. 1039901, https://doi.org/10.3389/fonc.2023.1039901.